

[REDACTED]

Dtd. Shillong, the 16th Aug., 202

Ref :- [REDACTED]

Dt. Shillong, the 01.08.2
Dt. Shillong, the 04.08.2

Sir/Madam,

Kindly find herewith the analytical report of the following Survey Sample of Drugs. This has reference to the letter cited above.

The details of the report are also enclosed for necessary.

Registration No.	Name of samples	Manufacturer	Batch No.	Mfg. Date	Ex Da
[REDACTED]	Cefixime Tabs	[REDACTED]	23CT024	07/23	06/
[REDACTED]	Maxcef Oral Suspension	[REDACTED]	23CS042	07/23	06/

[REDACTED]

Dtd. Shillong, the 16th Aug., 202

[REDACTED]

Name of the sample and content:

CEFIXIME TABLET

Each uncoated tablet contains:

Cefixime Trihydrate IP

Eq. to Anhydrous Cefixime.....100mg

Excipients.....q.s.

Colour: Titanium Dioxide IP

Manufacturer's name & address:



Date received: **02.08.2023**

REGISTRATION No.



Batch No. **23CT024**

Mfg. Date **07/23**

Exp. Date **06/25**

Permitted
Limits

Description: Round tablets, white in colour with raised surfaces and smooth edges.

Uniformity of Weight: Conform to specifications prescribed in IP.

Identification Tests: Conform to specifications prescribed in IP.


Disintegration: All tablets disintegrates within 5 mins..

ASSAY: By HPLC

% Content of active component in sample = 96.7%

90-110%

REMARKS: SAMPLE PASSED THE TESTS PERFORMED




Dated: Shillong

The 16/8/23

Name of the sample and content: **MAXCEF ORAL SUSPENSION**

Each 5ml reconstitution Suspension contains:
Cefixime Trihydrate IP
Eq.to Cefixime.....50mg
Excipients.....q-s.
Colour: Approved colour used

Manufacturer's name & address:



Date received: **07.08.2023**

REGISTRATION No.

Batch No. **23CS042**

Mfg. Date **07/23**

Exp. Date **06/24**

Permitted
Limits

Description: Light orange amorphous powder. When reconstituted as directed the suspension becomes bright orange in colour.

Uniformity of Weight: Conform to specifications prescribed in IP.

Identification Tests: Conform to specifications prescribed in IP.

Wt/ml: Conform to specifications prescribed in IP.

pH : 4.2 2.5-4.5

ASSAY: % Content of active component in sample = 106.9% 90-120%
Stability Test 98% > 80%

REMARKS: SAMPLE PASSED THE TESTS PERFORMED



Dated: Shillong
The 16/8/23